On Wednesday, Novo Nordisk A/S (NYSE:NVO) announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint. CLARION-CKD was a multicenter, double-blind, placebo-controlled, randomized phase 3 study of ocedurenone for uncontrolled hypertension in patients with advanced chronic kidney disease (CKD). Also Read: Novo Nordisk Releases Data Showing Ozempic For Diabetes Slows Kidney Disease Progression. CLARION-CKD follows the same inclusion criteria as the phase 2b BLOCK-CKD study, which achieved its primary endpoint with clinical and statistical significance. More than 600 patients were randomized for the CLARION-CKD trial. Novo Nordisk acquired ocedurenone ...